Multi-center Study to Assess Safety, Tolerability & Efficacy of Topical

Status Active, not recruiting

Clinical Trial Summary

This is a randomized, open label, controlled, multi-center study to assess safety, tolerability, and efficacy of adjunctive treatment with topically applied pravibismane (MBN-101) in patients with moderate diabetic foot infections. Patients will be randomized in a 2:1 ratio (MBN-101:standard of care). Topical pravibismane (MBN-101) will be applied three times per week for up to 12 weeks. All patients will receive systemic antibiotic treatment for a least a portion of that period. Randomization will be stratified by site.

Clinical Trial Description

This is a randomized, open label, controlled, multi-center study. Patients with diabetes mellitus (either type 1 or 2) and an infected wound of the foot with an International Working Group Diabetic Foot (IWGDF) severity rating of moderate will be eligible for the trial after meeting all inclusion criteria and none of the exclusion criteria. Patients (n = 54) will be randomized in a 2:1 ratio (MBN-101: standard of care). Randomization will be stratified by site. Patients randomized to the MBN-101 arm will be treated in an outpatient facility 3 times per week for the first 2 weeks. During each of the subsequent 10 weeks, patients will be treated once per week at the outpatient clinic and will be provided with enough MBN-101 for 2 additional days of treatment for self administration at home with or without the assistance of a caregiver. The duration between each dose should be greater than 24 hours, yet not exceed 72 hours for each of the 12 treatment weeks. Patients randomized to the standard of care arm will follow the same schedule (i.e., inclusive of wound dressing changes), though will not be treated with MBN-101. All subjects will initially receive systemic antibiotic treatment and undergo appropriate sharp debridement at baseline and then as directed by the treating physician through the 12-week treatment period, yet part of the standard of care treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05174806
Study type	Interventional
Source	Microbion Corporation
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	June 13, 2022
Completion date	March 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06154915` - Immune Cells in Diabetic Chronic Foot Ulcers
Completed	`NCT04624516` - Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence	N/A
Completed	`NCT02373592` - Implementation of Foot Thermometry and SMS and Voice Messaging to Prevent Diabetic Foot Ulcer	N/A
Active, not recruiting	`NCT01903044` - Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating	Phase 1/Phase 2
Completed	`NCT02092870` - Adipose Derived Regenerative Cellular Therapy of Chronic Wounds	Phase 2
Completed	`NCT01212120` - The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections	N/A
Completed	`NCT00402727` - Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection	Phase 3
Recruiting	`NCT04085705` - The Prevalence of Contact Allergies for Wound Dressings In Patients With Diabetic Foot Ulcers (PAID Study)
Completed	`NCT04054804` - Digital Foot Check by Using the D-Foot, a New Software
Completed	`NCT04480801` - The Effect of Thermal Evaluation in Prevention of Diabetic Foot Ulcer	N/A
Not yet recruiting	`NCT04537676` - Patient Empowerment Study
Recruiting	`NCT04564443` - A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot	N/A
Recruiting	`NCT05974592` - The Effect of Nurse-Led Diabetic Foot Self-Management Training Program	N/A
Not yet recruiting	`NCT04630795` - ViscoTurf - Preventing Secondary Diabetic Foot Ulceration.
Not yet recruiting	`NCT05431660` - Diabetic Foot School and Biomechanics	N/A
Completed	`NCT05101473` - Exercise Therapy for People With a Diabetic Foot Ulcer - a Feasibility Study	N/A
Completed	`NCT05123157` - Pattern and Type of Amputation and Mortality Rate Associated With Diabetic Foot in Jeddah, Saudi Arabia: A Retrospective Cohort Study
Enrolling by invitation	`NCT05043636` - Diabetic Neuropathy Screening Study 1.1 + Substudy 1.2-1.3-1.4
Completed	`NCT03254095` - Predictors of Skin Temperature, Plantar Pressure and Ulceration in Diabetic Foot Patients.
Terminated	`NCT01657318` - Olivamine-containing Products in the Management of Patients With Nonhealing Lower Extremity Ulcers

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms